What is Meduloc?
Founded in 2016 by a consortium of orthopedic hand surgeons and Cor Medical Ventures, Meduloc specializes in the design and manufacturing of minimally invasive, intramedullary implants. The company's core value proposition centers on providing stable fixation and secure reduction for bone fractures, effectively bridging the gap between traditional surgical methods and modern, high-precision medical technology. Beyond its product portfolio, Meduloc distinguishes itself through a comprehensive service model that encompasses product development, regulatory support, and strategic commercialization guidance. The firm is supported by an advisory board of seasoned surgeons, ensuring that its technological roadmap remains aligned with the evolving needs of the global healthcare community.
How much funding has Meduloc raised?
Meduloc has raised a total of $5.8M across 2 funding rounds:
Stock/Share Issuance
$1.8M
Series B
$4M
Stock/Share Issuance (2026): $1.8M, investors not publicly disclosed
Series B (2026): $4M led by GenHenn Capital and Broad Street Angels
Key Investors in Meduloc
GenHenn Capital
GenHenn Capital is a venture capital firm focused on investing in early-stage life sciences, healthcare, and biotech companies that are developing high-impact solutions.
Broad Street Angels
Broad Street Angels is a Philadelphia-based angel investment club that focuses on providing funding opportunities for entrepreneurs in the Mid-Atlantic region.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Meduloc?
With the successful closure of this Series B round, Meduloc is expected to prioritize the scaling of its manufacturing capabilities and the expansion of its clinical support network. The strategic allocation of these funds will likely focus on accelerating the regulatory approval processes in new international markets and enhancing the company's internal finance and fundraising support services. As the firm continues to refine its internal fixation solutions, the focus will remain on maintaining high clinical efficacy while optimizing the supply chain to meet the increasing demand for minimally invasive orthopedic interventions. This growth trajectory suggests a long-term commitment to establishing Meduloc as a standard-bearer in the orthopedic implant industry.
See full Meduloc company page
